Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Total Equity: €5,258 Mil (As of Mar. 2026)

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Total Equity?

Guangzhou Baiyunshan Pharmaceutical Holdings Co FRA:GU5 +1.87% 68 Total Equity is €5,258 Mil as of Mar. 2026. GuruFocus rates FRA:GU5 with a GF Score™ of 68/100 and a GF Value™ of €2.38 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's total equity for the quarter that ended in Mar. 2026 was €5,258 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Total Equity Related Terms

Guangzhou Baiyunshan Pharmaceutical Holdings Co Total Equity Historical Data

* Premium members only.

The historical data trend for Guangzhou Baiyunshan Pharmaceutical Holdings Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Total Equity Chart

Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Equity

Get a 7-Day Free Trial

4,352.77

4,554.72

4,710.45

4,954.19

4,860.12

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Equity	Get a 7-Day Free Trial															5,057.87	4,807.02	4,782.26	4,860.12	5,257.78

68GF Score

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5

Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2025 )	-	Total Liabilities(Q: Dec. 2025 )
	=	10247.12	-	5387.004
	=	4,860

Guangzhou Baiyunshan Pharmaceutical Holdings Co's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2026 )	-	Total Liabilities(Q: Mar. 2026 )
	=	11265.153	-	6007.374
	=	5,258

Frequently Asked Questions Learn more about Total Equity →

What does a Total Equity of €5,258 Mil mean?

Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Total Equity of €5,258 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Total Equity too high?

Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Total Equity is €5,258 Mil. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Total Equity compare to MCK and CAH?

Guangzhou Baiyunshan Pharmaceutical Holdings Co's Total Equity of €5,258 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Equity for a Medical Distribution company?

A good Total Equity depends on the Medical Distribution industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Equity mean?

A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Total Equity is €5,258 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.38, compared to a current price of €1.63 — trading 31.5% below its estimated fair value. The current Total Equity is €5,258 Mil. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Equity calculated?

Total Equity is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Total Equity is €5,258 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of €1.63 is trading 31.5% below its estimated GF Value™ of €2.38. GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.

Key valuation signals for FRA:GU5:

Total Equity: €5,258 Mil
GF Value™: €2.38 vs. price of €1.63 (31.5% below fair value)
GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description

Industry Healthcare Medical Distribution

Comparable Companies SHSE:600998 SHSE:600511 SHSE:600739 SHSE:600056 SZSE:000028 SZSE:301015 SHSE:601607 SZSE:000950 SZSE:301584 SHSE:603368 MCK CAH COR ASX:SIG HSIC HKSE:01099 XSWX:GALE TSE:7459 OSTO:ASKER MIL:AMP

Other Exchanges 00874:Hong Kong 600332:China

Address 45 Sha Mian North Street, Liwan District, Guangdong Province, Guangzhou, CHN, 510130

Website https://www.gybys.com.cn

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.

68GF Score

Get the complete analysis for FRA:GU5

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63

Price

€2.38

GF Value

View FRA:GU5 Analysis

See Total Equity data for all stocks →